Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

Completed · Phase 2/Phase 3

Conditions studied: Alzheimer Disease

In brief

The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.

Key facts

Study ID

NCT00065767

Run by

University of Wisconsin, Madison

People needed

20

Starts

2001-09-01

Expected to finish

2005-03-01

Last updated by the study team

2015-10-05

Who can join

Age: 55 and older, up to 90. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Postmenopausal women with Alzheimer's disease and without other dementias (diagnosed by study staff or from an outside clinic)
• Mini Mental Status Exam score greater than 15/30

You may not qualify if…

• History of deep vein thrombosis or blot clots
• Diabetes
• Active heart disease or stroke
• Liver problems including hepatitis
• Severe vision or hearing problems
• Tobacco use

Where it is running

• University of Wisconsin Memory Research Program — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.